[ad_1] The new immuno-oncological drug from Sanofi and Regeneron may well be the sixth member of its class to get FDA approval, but it already has something that all its predecessors have …
Read More »Sanofi, sixth on the market, wins a niche for the PD-1 player and the big hit, Libtayo
